Inhibrx Biosciences (INBX)

Executive Summary

Inhibrx Biosciences (NASDAQ: INBX) is a clinical-stage biopharmaceutical company leveraging its proprietary single-domain antibody (sdAb) platform to develop novel therapies for oncology and orphan diseases. The company's pipeline includes six candidates, with lead programs INBRX-109 targeting death receptor 5 (DR5) in sarcomas and INBRX-106 targeting OX40 in solid tumors. INBRX-109 is in a Phase 2 trial for conventional chondrosarcoma (a rare bone cancer with no approved therapies) and a Phase 1/2 trial in Ewing sarcoma. INBRX-106 is in a Phase 2/3 study for head and neck squamous cell carcinoma (HNSCC) and a Phase 2 study for triple-negative breast cancer (TNBC), both in combination with pembrolizumab. The company went public in 2021 and has a market capitalization of approximately $1.8 billion. Inhibrx's sdAb platform enables multi-specific, multi-functional biologics with favorable pharmacokinetics, potentially addressing high unmet medical needs. Near-term value drivers include upcoming clinical data readouts from its lead programs, which could validate the platform and support regulatory milestones.

Upcoming Catalysts (preview)

• H2 2026INBRX-109 Phase 2 top-line data in conventional chondrosarcoma35% success
• H1 2027INBRX-106 Phase 2/3 interim efficacy data in HNSCC30% success
• H2 2027INBRX-106 Phase 2 initial data in TNBC25% success